Bocidelpar sulfate is under clinical development by Mitobridge and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bocidelpar sulfate’s likelihood of approval (LoA) and phase transition for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) took place on 09 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bocidelpar sulfate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bocidelpar sulfate overview

MA-0211 is under development for the treatment of Duchenne muscular dystrophy (DMD), mitochondrial myopathies and fatty acid oxidation disorders including Melas syndrome, Kearns-Sayre syndrome. It is administered through oral route. The drug candidate acts by targeting peroxisome proliferator-activated receptor delta (PPARdelta). It was also under development for Leber’s hereditary optic neuropathy (LHON).

Mitobridge overview

Mitobridge, formerly Mitokyne, a subsidiary of Astellas Pharma Inc is a drug development company. It discovers and develops small molecule therapeutics that recovers mitochondrial functions. The company develops therapies for rare diseases and expands into more common diseases. Mitobridge utilizes screening platform to identify and develop novel therapeutics. In addition, The company holds expertise in the areas of mitochondrial genetic diseases, musculoskeletal, liver disease, kidney, neurodegenerative disorders and diseases and conditions of aging. It works in collaboration with companies in the field of mitochondrial biology and medicine. Mitobridge is headquartered in Cambridge, Massachusetts, the US.

Quick View Bocidelpar sulfate LOA Data

Report Segments
  • Innovator
Drug Name
  • Bocidelpar sulfate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Musculoskeletal Disorders
  • Ophthalmology
Key Developers
  • Sponsor Company: Mitobridge
  • Originator: Salk Institute for Biological Studies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.